ARTICLE | Clinical News
rhNGF recombinant human nerve growth factor regulatory update
July 15, 2013 7:00 AM UTC
Dompe said the European Commission granted Orphan Drug designation for its rhNGF to treat retinitis pigmentosa. The product is in the Phase I/II REPARO trial to treat neurotrophic keratitis. Dompe gai...